Side-by-side · Research reference
PinealonvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft12/36 cited
BPhase 3Reviewed8/39 cited
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Pinealon
Thymosin α-1
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Pinealon
Thymosin α-1
Frequency
Once daily during cycle
2× weekly (Mon/Thu typical)
Lower / starter dose
2.5 mg / day
0.8 mg per injection
Evidence basis
Russian clinical trials + in vitroKhavinson 2014
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
10-day cycles, 1–2× per year
6–12 months for chronic indications
Reconstitution
Bacteriostatic water
Sterile water for injection per vial label
Timing
No specific time
No specific time
Half-life
Hours
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
Pinealon
Thymosin α-1
Injection site reaction
Mild irritation
Erythema, mild discomfort
Long-term safety
Limited Western data
—
Pregnancy / OB
Avoid
Avoid
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Absolute Contraindications
Pinealon
- ·Pregnancy / breastfeeding
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Pinealon
Thymosin α-1
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Injection site
SQ — abdomen preferred.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Daily during cycle, any time.
2× weekly, e.g. Monday + Thursday.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation
Thymosin α-1
— no documented stacks